TNYA
Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. (TNYA) has 5 SEC Form 4 filings (11 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: May 19, 2026.
The most active filer is 10% Owner COLUMN GROUP III GP, LP with 4 filings. Insiders have net sold $2.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Faraz Ali
- Employees:70
- HQ:South San Francisco, CA, US
- IPO:2021-07-30
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.9M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$158.2M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Higa TomohiroFirst filing | SVP, Finance | Sale | 1,485 | $1K | May 19 | SEC ↗ |
Ali FarazFirst filing | Chief Executive Officer | Sale | 3,390 | $3K | May 19 | SEC ↗ |
Tingley WhittemoreFirst filing | Chief Medical Officer | Sale | 3,121 | $2K | May 19 | SEC ↗ |
| 10% Owner | Sale | 658,440 | $405K | Feb 26 | SEC ↗ | |
| 10% Owner | Sale | 3,511,826 | $2.0M | Feb 26 | SEC ↗ | |
COLUMN GROUP III GP, LPFirst filing | 10% Owner | Sale | 523,734 | $322K | Feb 24 | SEC ↗ |
COLUMN GROUP III GP, LPFirst filing | 10% Owner | Sale | 306,000 | $183K | Feb 24 | SEC ↗ |
Related companies
Tenaya Therapeutics, Inc. is in the Healthcare sector.